Clinical trial: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Status: RECRUITING
Conditions: Advanced Breast Carcinoma|Advanced Endometrial Carcinoma|Advanced Fallopian Tube Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Malignant Abdominal Neoplasm|Advanced Malignant Female Reproductive System Neoplasm|Advanced Malignant Thoracic Neoplasm|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Renal Cell Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Malignant Abdominal Neoplasm|Malignant Solid Neoplasm|Metastatic Breast Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Malignant Abdominal Neoplasm|Metastatic Malignant Female Reproductive System Neoplasm|Metastatic Malignant Thoracic Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Renal Cell Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8
Interventions: BIOLOGICAL: Atezolizumab|DRUG: Cabozantinib S-malate|DRUG: Nab-paclitaxel|PROCEDURE: Tumor Treating Fields Therapy
Study Type: INTERVENTIONAL
Study Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT